PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.89%
Both companies show declining cash positions (-7.89% vs TRAW's -23.86%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.89%
Below half of TRAW's -23.86%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
Below half of TRAW's -17.60%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-4.83%
Below half TRAW's -10.71%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.38%
Below half of TRAW's -10.17%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Below half of TRAW's -17.51%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-25.56%
Above 1.5x TRAW's -15.02%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-49.71%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
240.62%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
-18.75%
Exceeding 1.5x TRAW's -1.40%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-24.27%
Less than half of TRAW's 19.01%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.27%
Less than half of TRAW's 10.39%. David Dodd sees far fewer liability expansions relative to competitor.
5.27%
Less than half of TRAW's -90.15%. David Dodd sees fewer share issuances vs. competitor.
-5.68%
≥ 1.5x TRAW's -1.65%. David Dodd sees higher yoy retained profits than competitor.
-17.53%
Similar yoy to TRAW's -18.75%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half TRAW's -79.68%. Michael Burry sees potential underperformance in building shareholder capital.
-7.59%
Below half TRAW's -17.51%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-49.71%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
7.55%
Less than half of TRAW's 23.86%. David Dodd sees better deleveraging or stronger cash buildup than competitor.